Budesonide - a new nasal steroid

39 patients with seasonal rhinitis entered a double-blind study comparing nasal sprays of budesonide 400 micrograms/day and placebo. Symptoms were assessed over a treatment of of three weeks. There were statistically significant differences in favour of the active spray on all measures of assessment. Side effects were mild and the incidence was negligible.